Stockreport

Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 [Seeking Alpha]

Oruka Therapeutics, Inc.  (ORKA) 
PDF Net cash used in operating activities was $21.6 million for the third quarter of 2025. More on Oruka Therapeutics Oruka jumps as lead drug outperforms AbbVie's Skyr [Read more]